您当前的位置：
首页 >
文章列表页 >
Safety and effectiveness of ustekinumab for Crohn's disease
Medical Journal of Chinese People′s Liberation Army   Vol. 50, Issue 10, Pages: 1277-1283(2025)
Clinical Research | 更新时间：2025-11-05

    • Safety and effectiveness of ustekinumab for Crohn's disease

      增强出版
    • “The treatment of moderate to severe Crohn's disease with monoclonal antibodies against ustekinumab shows significant efficacy and good drug safety. The clinical response at week 14 is correlated with clinical remission at week 52.”

    • DOI：10.11855/j.issn.0577-7402.0841.2025.0306    

      CLC： R574.1

    • Received：13 June 2024，

      Accepted：14 July 2024，

      Published Online：06 March 2025，

      Published：28 October 2025

    移动端阅览

  • Liu Liu,Jiang Ke-Fang,Chen Yi-Fei,et al.Safety and effectiveness of ustekinumab for Crohn's disease[J].Medical Journal of Chinese People′s Liberation Army,2025,50(10):1277-1283. DOI： 10.11855/j.issn.0577-7402.0841.2025.0306.

  •  
  •  

0

Views

0

下载量

0

CSCD

0

CNKI被引量

>
Alert me when the article has been cited
提交
Outline
No Sections

Related Articles

Efficacy and safety of minimally invasive surgery in treatment of severe tricuspid incompetence after left cardiac valve surgery
Systematic review of biologic therapy safety in pregnant and breastfeeding psoriasis patients
Progress in study of gut non-immune cells and their role in development of inflammatory bowel disease
Efficacy evaluation and prognostic factors analysis of retinoblastoma based on propensity score inverse probability weighting method

Related Author

Jiang Sheng-Li
Liu Bing
Zhang Xiao-Yan
Gu Zheng
Wang Hui-Jing
Fang Yu-Shi
Li Zi
Li Zong-Yang

Related Institution

Medical School of Chinese PLA
Department of Cardiovascular Surgery, the First Medical Center of Chinese PLA General Hospital
Department of Dermatology, China-Japan Friendship Hospital
Graduate School, Beijing University of Chinese Medicine
Senior Department of Gastroenterology, the First Medical Center of Chinese PLA General Hospital
0